GSE138464
Overcoming Resistance to Anabolic SARM therapy in Experimental Cancer Cachexia with an HDAC Inhibitor
No approved therapy exists for cancer-associated cachexia.  The colon-26 mouse model of cancer cachexia mimics recent late stage clinical failures of anabolic anti-cachexia therapy, and was unresponsive to anabolic doses of diverse androgens, including the selective androgen receptor modulator (SARM) GTx-024.  The histone deacetylase inhibitor (HDACi) AR-42 exhibited anti-cachectic activity in this model.  We explored combined SARM/AR-42 therapy as an improved anti-cachectic treatment paradigm.  A reduced dose of AR-42 provided limited anti-cachectic benefits, but, in combination with GTx-024, significantly improved body weight, hind limb muscle mass, and grip strength versus controls.  AR-42 suppressed the IL-6/GP130/STAT3 signaling axis in muscle without impacting circulating cytokines.  GTx-024-mediated ß-catenin target gene regulation was apparent in cachectic mice only when combined with AR-42.  Our data suggest cachectic signaling in this model involves catabolic signaling insensitive to anabolic GTx-024 therapy and a blockade of GTx-024-mediated anabolic signaling.  AR-42 mitigates catabolic gene activation and restores anabolic responsiveness to GTx-024. Combining GTx-024, a clinically established anabolic therapy, with AR-42, a clinically evaluated HDACi, represents a promising approach to improve anabolic response in cachectic patients. Overall design: 31 Samples